Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for IMUX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -0.249M
March 31, 2026 -0.002M
December 31, 2025 -0.011M
September 30, 2025 -0.067M
June 30, 2025 -0.036M
March 31, 2025 -0.047M
December 31, 2024 -0.003M
September 30, 2024 -0.05M
June 30, 2024 -0.18M
March 31, 2024 -0.031M
December 31, 2023 -0.165M
September 30, 2023 -0.044M
June 30, 2023 4.336M
March 31, 2023 5.335M
December 31, 2022 -9.628M
September 30, 2022 -0.073M
June 30, 2022 -0.028M
March 31, 2022 -0.012M
December 31, 2021 -0.019M
September 30, 2021 -0.02M
June 30, 2021 -0.018M
March 31, 2021 -0.01M
December 31, 2020 -0.024M
September 30, 2020 -0.063M
June 30, 2020 -0.055M
Date Value
March 31, 2020 -0.004M
December 31, 2019 -0.025M
September 30, 2019 1.237M
June 30, 2019 9.331M
March 31, 2019 -0.007M
December 31, 2018 -0.02M
September 30, 2018 -0.005M
June 30, 2018 0.143M
March 31, 2018 -0.15M
December 31, 2017 -0.111M
September 30, 2017 -0.169M
June 30, 2017 -0.127M
March 31, 2017 -0.271M
December 31, 2016 -0.119M
September 30, 2016 -0.272M
June 30, 2016 -0.04M
March 31, 2016 -0.123M
December 31, 2015 0.488M
September 30, 2015 0.036M
June 30, 2015 -1.19M
March 31, 2015 -0.615M
December 31, 2014 -0.183M
September 30, 2014 -0.541M
June 30, 2014 -0.463M
March 31, 2014 -0.853M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. -8.529M
Sionna Therapeutics, Inc. 21.47M
Alnylam Pharmaceuticals, Inc. -363.46M
Anika Therapeutics, Inc. -1.28M
Savara, Inc. 32.60M